>>Countdown to our free event: Meet the Real Money Pros: Market Strategies for 2012
NEW YORK (
CHANGE IN RATINGS, EPS
Abercrombie & Fitch
(ANF - Get Report)
cut from Conviction Buy List at Goldman. Valuation call, as the stock is up 32% over the past 11 months.
upgraded at Goldman from Sell to Neutral. The company can expand margins in the coming quarter.
downgraded to sell at TheStreet Ratings.
numbers adjusted at Citigroup. Shares of AMT now seen reaching $65. Estimates lowered on FX headwinds. Buy rating.
American Tower estimates, target raised at JP Morgan. Shares of AMT now seen reaching $62. Estimates also increased on Core and Sprint MLA.
estimates increased at UBS. ABC estimates increased through 2013. Positive operating trends. Maintain $47 price target and Buy rating.
downgraded at Goldman from Neutral to Sell. Margins are peaking and the company is leveraged to slower macro growth.
Archer Daniels Midland
(ADM - Get Report)
numbers cut at Morgan Stanley. Shares of ADM now seen reaching $37. Estimates also reduced, given lower oilseed margins. Overweight rating.
downgraded at Needham from Strong Buy to Buy. Company could face inventory rebalancing in the next couple of quarters.
Atmel upgraded to buy at TheStreet Ratings.
target cut at UBS to $43. VARs continue to plod through a sluggish economic environment. Buy rating.
(BHI - Get Report)
numbers cut at Credit Suisse. Shares of BHI now seen reaching $80. Estimates also reduced, given lower expected North American pricing. Outperform rating.
Baker Hughes estimates increased at Sterne Agee. BHI estimates raised through 2012. Bullish rig count forecast. Maintain $71 price target and Buy rating.
Baker Hughes estimates, target cut at UBS. Shares of BHI now seen reaching $82. Estimates also increased as overall story is still in on track despite a sloppy 3Q. Buy rating.
numbers lowered at Credit Suisse. Shares of CHSI now seen reaching $62. Estimates also cut, to match the company's new guidance. Outperform rating.
(CAT - Get Report)
rated new Overweight at Morgan Stanley. Valuation call, based on a $125 price target.
(CME - Get Report)
numbers lowered at Jefferies. CME estimates were cut through 2012. Volume has moderates and expenses could be back on the rise. Buy rating and new $297 price target.
CME Group estimates lowered at UBS through 2012. MF Global bankruptcy may be a blow to the futures industry as a whole. Buy rating.